Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Latest news

Sign up for updates

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 13/11/2018
    • Articles

    UK House of Commons Health and Social Care Committee Makes Broad Pricing Information Request Regarding Orkambi®

    The Chair of the Health and Social Care Committee of the UK House of Commons wrote on 7 November 2018 to Vertex, the National Health Service (“NHS England”) and the National Institute for Health and Care Excellence (“NICE”) to request pricing information regarding the cystic fibrosis medicine Orkambi® (see attached letters). The move follows two-and-a-half years of unsuccessful pricing negotiations between these parties.

    Read more
    • 12/11/2018
    • Articles

    New Belgian Ultimate Beneficial Owners Register

    The Royal Decree of 30 July 2018 (the Royal Decree), which entered into force on 31 October 2018, sets out the legal framework in relation to the new central register of beneficial ownership (the UBO Register) and the obligation for all Belgian companies and other entities to communicate information in relation to their ultimate beneficial owner(s) (UBOs) for inclusion in the UBO Register.

    Read more
    • 09/11/2018
    • Articles

    Belgian Competition Authority Adopts Draft Decision Against Professional Organisation of Pharmacists

    The College of Prosecutors of the Belgian Competition Authority (“BCA”) announced on 8 November 2018 that it has submitted a draft infringement decision to the Competition College with the request to review the Prosecutors’ findings and take a final decision against the professional organisation of pharmacists known as “Orde der Apothekers”/”Ordre des pharmaciens” (the “PO”).

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.